MustGrow Reports 100% Control of Banana Disease at Economic Rates; Advancing to Field Trials in Colombia
- 100% control of Fusarium wilt TR4 disease at economic rates as low as 5 gal/acre (49 L/ha).
- National State of Emergency declared in Colombia in 2019.
- Fusarium wilt TR4 is existential threat to the $25 billion global banana industry.
- MustGrow advancing to field study trials.
MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce further laboratory results of its mustard-derived natural biopesticide on the disease Fusarium wilt TR4 (“Fusarium wilt TR4”). Fusarium wilt TR4 (previously referred to as the Panama Disease) is a devastating pathogen ravaging the $25 billion global banana industry. Testing and reporting in this second Colombia study was completed by a different third party independent laboratory than was used in the first study to add further validation.
MustGrow’s safe and effective natural biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds.
- 100% control as low as 5 gal/acre (49 L/ha);
- Confirmation of economical rates in laboratory;
- Field study trials to commence.
Fusarium wilt TR4 samples were treated with MustGrow’s mustard-based liquid biopesticide at various low-rate applications which demonstrated 100% control, and also potential economical proficiency if extrapolated to a plantation field scenario. 100% control was achieved at economic rates as low as 5 gal/acre (49 L/ha) within a 3 day testing period. In comparison, control samples (without MustGrow’s product) showed Fusarium wilt TR4 was still vibrant and growing. These results further strengthen MustGrow’s body of work in Colombia as preparation accelerates for its highly-anticipated field studies.
On Dec. 1, 2020, MustGrow announced it had successfully controlled (100% kill) Fusarium wilt TR4 definitively in a laboratory setting – a unique feat MustGrow believes no other agri-science team has achieved. MustGrow’s cumulative laboratory work has reaffirmed its approach to simultaneously pursue a potential “fast-track” registration in Colombia. Additionally, MustGrow believes its work in Colombia will serve as a beachhead to expand into other leading banana producing countries.
Colin Bletsky, COO of MustGrow, commented, “With this additional efficacy confirmation, we are very excited about the opportunity to potentially help the banana industry manage this devastating disease. Reproduction of the same positive results through yet another independent laboratory has further validated our approach. With a more defined dose response, we are now ready to commence field testing with deeper refinement of our study design.”
Fusarium wilt TR4
Fusarium wilt TR4 is the world’s most destructive banana disease, affecting particularly Cavendish bananas, which comprise half of global banana production. Currently, there are no effective treatments for infected banana plantations, with the disease remaining viable in soil for decades and can cause 100% yield loss. The spread of Fusarium wilt TR4 through banana plantations in South America has prompted Colombia to reportedly declare a National State of Emergency, enacting special measures to stop the disease from spreading, including the preventive eradication of infected plantations. A flurry of media reports has followed, revealing a race to save bananas from extinction after the disease has left a trail of scorched banana plantations in its wake.
MustGrow is a publicly traded (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables and other industries. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a biopesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a mustard extract in liquid format, TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest disease control and food preservation.
The Company has approximately 42.0 million basic common shares issued and outstanding and 50.6 million shares fully diluted. For further details please visit www.mustgrow.ca.
ON BEHALF OF THE BOARD
Director & CEO
Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.
These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
© 2021 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73949
News Provided by Newsfile via QuoteMedia
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.